AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biotage

Report Publication Announcement Apr 8, 2009

2894_rns_2009-04-08_891cfb4e-c678-4056-8134-c215f47dfb0c.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Press release Biotage AB

Contact: SE-753 18 Uppsala Torben Jörgensen, President and CEO Tel+46 18 56 59 00 Tel: +46 707 49 05 84, [email protected] www.biotage.com

Kungsgatan 76

Uppsala April 8, 2009

Biotage AB (publ) releases its 2008 Annual Report

Biotage is today releasing its 2008 annual report.

The company generated net sales of 385,3 MSEK (397,6 MSEK).

The operating result amounted to 22,5 MSEK (16,7 MSEK) and total profit after tax for the year of 299,1 MSEK (99,4 MSEK).

Total profit per share of 3,38 SEK (1,12 SEK).

Financial Goals 2009 and onwards

Biotage business is under changes after the divestment of the Biosystems business and the ongoing restructuring of the remaining Discovery Chemistry business. The decision to close down the factory in Charlottesville, Virigina, and to outsource the manufacturing of Biotage's instrument, results in relatively big organizational and operational changes. By reason hereof new more specific financial goals will be set during the latter part of 2009, when the effects from the ongoing changes may be measured more in detail. Short term Biotage will adjust the organization to the new conditions and will re-establish organic growth in the business. At the same time Biotage will profit from its strong financial position and seek to acquire attractive businesses or products.

The full report is available at: Annual Report 2008

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the area of medicinal chemistry. In 2005 business and products from the company Argonaut were acquired, further strengthening the product range in medicinal chemistry. The customers include the worlds top 30 pharma companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany and several other European countries. Biotage has 300 employees and had sales of 385,3 MSEK in 2008. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: www.biotage.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.